CADL
Candel Therapeutics, Inc. [CADL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CADL Stock Summary
Top CADL Correlated Resources
CADL
Top 10 Correlated ETFs
CADL
Top 10 Correlated Stocks
CADL
In the News
CADL Financial details
Company Profile
- Volume Average 5.22M
- Market Capitalization 195.45M
- Employee 42
- CEO Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
- Headquarters Needham,MA,US
- IPO Date 2021-07-27
-
Website
https://www.candeltx.com 
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
